Refreshments available from 13:30

COMPLEX BIOSIMILARS: ARE WE FULLY PREPARED?



Wednesday, 16 March 2016
Austria Center Vienna, Hall M
14:00 – 15:30

As the EMA begins to grant approval to biosimilar versions of TNFα antagonists and other complex proteins, pharmacists, patients and physicians will have many questions surrounding their introduction.

During this 90-minute symposium we will review some of the key challenges that surround the development and use of biosimilars, such as the manufacturing and development of complex biologics, how their structure relates to their function, the scientific evidence for non-medical switching, and the importance of traceability to pharmacovigilance.

Please join us and contribute your views — we look forward to welcoming you to this highly interactive session.

Supported by

abbvie

Refreshments available from 13:30

COMPLEX BIOSIMILARS: ARE WE FULLY PREPARED?

AGENDA

Time	Topic	Speaker
14:00 – 14:05	Introduction	Irene Krämer
14:05 – 14:30	Biologic Therapy Complexity and the Importance of Structure to Function	Leigh Revers
14:30 – 14:55	Switching Stable Patients: Is There Enough Scientific Evidence?	Juan Esplugues
14:55 – 15:20	Pharmacovigilance Considerations for Biosimilars: Naming and Traceability	Irene Krämer
15:20 – 15:30	Q&A and Summary	All



Floor plan:

The symposium will be held in Hall M, located on Level 1 of the Congress Center (green level)

Supported by abbvie